Quench Medical

Executive Summary

Quench Medical is a clinical-stage pharmaceutical company developing targeted inhalation therapies for lung diseases, with an initial focus on lung cancer. Leveraging its proprietary aerosol formulation and dry powder inhalation technologies, the company aims to deliver drugs directly to lung tissue, potentially improving efficacy while reducing systemic toxicity compared to oral or intravenous administration. Founded in 2018 and based in San Diego, Quench Medical is currently operating at the pre-clinical stage and is private, pre-revenue. The company's approach addresses a significant unmet need in lung cancer treatment, where local delivery could enhance therapeutic outcomes and minimize side effects. As Quench Medical advances its programs through pre-clinical development, its next milestones include completing IND-enabling studies, filing an Investigational New Drug application, and initiating first-in-human trials. The company's technology platform also holds promise for other respiratory diseases, positioning it for potential partnerships or licensing deals. However, as an early-stage private entity with no disclosed funding or partnerships, Quench Medical faces typical development risks and capital requirements.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Lung Cancer Program60% success
• Q3 2027First-in-Human Trial Initiation50% success
• Q2 2027Strategic Partnership or Licensing Deal30% success